Repligen Co. (NASDAQ:RGEN) Receives $184.73 Consensus Target Price from Analysts

Shares of Repligen Co. (NASDAQ:RGEN) have been assigned an average recommendation of “Moderate Buy” from the fifteen brokerages that are currently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $186.00.

Several research firms have issued reports on RGEN. Canaccord Genuity Group started coverage on Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. Canaccord Genuity Group started coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. TD Cowen assumed coverage on shares of Repligen in a report on Monday. They set a “buy” rating and a $200.00 price target for the company. HC Wainwright decreased their price objective on shares of Repligen from $240.00 to $180.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. Finally, Wolfe Research assumed coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating for the company.

Institutional Trading of Repligen

Several institutional investors and hedge funds have recently made changes to their positions in the business. Ballentine Partners LLC grew its stake in shares of Repligen by 4.0% during the fourth quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock worth $270,000 after purchasing an additional 72 shares during the period. CIBC Asset Management Inc boosted its holdings in Repligen by 5.0% during the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company’s stock worth $246,000 after buying an additional 81 shares during the last quarter. MML Investors Services LLC grew its position in shares of Repligen by 2.7% during the 3rd quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock worth $503,000 after buying an additional 89 shares during the period. GAMMA Investing LLC increased its stake in shares of Repligen by 15.2% in the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 90 shares during the last quarter. Finally, Louisiana State Employees Retirement System raised its position in shares of Repligen by 0.7% in the 4th quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company’s stock valued at $2,087,000 after acquiring an additional 100 shares during the period. Institutional investors own 97.64% of the company’s stock.

Repligen Stock Performance

NASDAQ RGEN opened at $145.72 on Thursday. Repligen has a twelve month low of $113.50 and a twelve month high of $211.13. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The stock has a market cap of $8.16 billion, a P/E ratio of -393.83, a PEG ratio of 4.54 and a beta of 0.99. The company’s 50-day simple moving average is $155.45 and its 200 day simple moving average is $149.14.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.09. The company had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The company’s revenue was up 9.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.23 EPS. As a group, research analysts forecast that Repligen will post 1.54 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.